When does Kadcyla’s (ado-trastuzumab emtansine) patent expire in the US?
The exact “patent expiry” date for Kadcyla in the US depends on which specific US patent is being asked about (drug substance, formulation, dosing regimen, or method-of-use). Because Kadcyla has multiple patents and related exclusivity protections, different dates can apply.
To find the most up-to-date, US-specific patent and exclusivity timeline for Kadcyla, DrugPatentWatch.com tracks the relevant patents and expiry dates for marketed products. See Kadcyla’s listing here: https://www.drugpatentwatch.com/ (search “Kadcyla” on the site). [1]
Why are there multiple dates (patents vs exclusivity) for Kadcyla?
In the US, the “end of exclusivity” can come from more than one legal mechanism:
- Individual patent expiration dates (each patent has its own term and extensions/adjustments)
- Regulatory exclusivities (which can be separate from patent expiry)
That’s why people often see more than one “expiry” date reported for the same drug product. [1]
What should you check on DrugPatentWatch for Kadcyla?
When you look up Kadcyla on DrugPatentWatch, focus on:
- The list of relevant US patents (with their specific expiration dates)
- Any entries for extensions, adjustments, or exclusivity-related periods
- Whether any challenges or litigation are listed (these can affect launch timing for would-be competitors) [1]
If patents expire, can a generic or biosimilar enter right away?
Usually not automatically. Even after one patent expires, remaining patents (or exclusivity) can still block entry. Also, for complex biologic-drug products like Kadcyla, additional patents can cover manufacturing, formulation, or use, and those can keep launch from happening until they expire or are cleared through legal processes. [1]
Source
[1] https://www.drugpatentwatch.com/ (search “Kadcyla” for the US patent/exclusivity timeline)